SCHEMBL3268922

SCHEMBL3268922

NC(=O)COC(=O)NCC1CN(c2cccc(C(F)(F)F)c2)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.46
POLB P06746 3/20 0.45
LMNA P02545 6/20 0.43
MAPK1 P28482 1/20 0.43
RAB9A P51151 1/20 0.43
ACACB O00763 2/20 0.43
ALDH1A1 P00352 3/20 0.42
MAPT P10636 2/20 0.41
HTT P42858 2/20 0.41
TSHR P16473 1/20 0.41
HTR3E A5X5Y0 1/20 0.41
HTR3B O95264 1/20 0.41
HTR1D P28221 1/20 0.41
HTR2C P28335 1/20 0.41
HTR3A P46098 1/20 0.41
HTR3D Q70Z44 1/20 0.41
HTR3C Q8WXA8 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
KDM4E B2RXH2 1/20 0.41
RECQL P46063 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3265530 0.87 POLB (0.46) NOTUMPOLBLMNAMAPK1RAB9A
SCHEMBL3266868 0.87 NOTUM (0.47) NOTUMPOLBLMNAMAPK1RAB9A
SCHEMBL2757289 0.83 NOTUM (0.43) NOTUMLMNAMAPK1ACACBALDH1A1
SCHEMBL1727883 0.83 NOTUM (0.55) NOTUMPOLBLMNAACACBALDH1A1
SCHEMBL240152 0.82 CHRM4 (0.56) NOTUMPOLBLMNAMAPK1RAB9A
SCHEMBL25080907 0.76 NOTUM (0.54) NOTUMPOLBACACBALDH1A1MAPT
SCHEMBL5231536 0.75 LMNA (0.70) POLBLMNAMAPK1RAB9AALDH1A1
SCHEMBL3265679 0.74 CHRM4 (0.50) LMNAACACBALDH1A1MAPTKDM4E
SCHEMBL3711639 0.73 CKS1B (0.51) NOTUMPOLBLMNAACACBSMN1; SMN2
SCHEMBL1729137 0.72 NOTUM (0.49) NOTUMPOLBLMNAMAPK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004207-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES SANOFI-AVENTIS (FR) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004207-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 NOTUM 3346/4885POLB 1541/4885LMNA 901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.